CGEM Cullinan Therapeutics, Inc.
$14.65▲ +0.72%
Healthcare
Other
Volume 160.2K
Avg Volume (10D) 715.3K
Key Metrics & Fundamentals
Market Cap
$900.05M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.73 - 23.19
% vs 50 MA
-20.96%
% vs 200 MA
-7.50%
RSI-14
41.1
MACD Histogram
+0.2000
Beta (1Y vs SPY)
1.62
Free Cash Flow
-$38.22M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$57.18M
COGS
–
Operating Exp
$57.25M
Operating Income
-$57.25M
EBIT
-$57.25M
Pretax Income
-$53.70M
Net Income
-$53.70M
EPS (Diluted)
-0.81
Price & Volume History
Loading chart…
Recent News
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
GlobeNewswire · Oct 27, 2026 7:00 AM ET
Cullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer Trial
MT Newswires · Oct 19, 2026 7:57 AM ET
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Business Wire · Oct 19, 2026 7:00 AM ET
Cullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid Leukemia
MT Newswires · Oct 8, 2026 7:39 AM ET
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire · Oct 8, 2026 7:00 AM ET
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
MT Newswires · Oct 2, 2026 9:19 AM ET
Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer
MT Newswires · Oct 2, 2026 4:10 AM ET
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
GlobeNewswire · Oct 1, 2026 7:30 PM ET
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
MarketBeat · Sep 28, 2026 7:02 AM ET
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
Simply Wall St. · Sep 26, 2026 6:07 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CGEM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.